Finland· FI-REL-REL51193

Veyvondi

A von willebrand factor product containing vonicog alfa, registered in Finland by Baxalta Innovations GmbH. The same ATC class is registered in 11 of our 19 countries.

ATC B02BD10

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedVeyvondiATCB02BD10REGISTER NO.FI-REL-REL51193PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Von willebrand factor is registered in 11 of 19 countries.

Countries holding a registration under ATC B02BD10 (von willebrand factor), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 7 of them publish a price we can compare per daily dose

Von willebrand factor · ATC B02BD10

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Vonicog alfa
Manufacturer
Baxalta Innovations GmbH
Country
Finland (FI)
ATC code
B02BD10
ATC class
Von Willebrand factor
Defined daily dose
1.5 TSD, E
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for von willebrand factor.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Von willebrand factor · interactions on record

2 records

  • 2 severe

Most severe, free to view

  • CarfilzomibL01XG02severe
  • CarfilzomibL01XX45severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f268ea5e-4db9-4655-a975-3be90298c9c0
GET /v1/drugs/f268ea5e-4db9-4655-a975-3be90298c9c0?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": null,
  "form": "injektiokuiva-aine ja liuotin, liuosta varten",
  "route": "Laskimoon",
  "ddd_unit": null,
  "strength": "1300 IU",
  "atc_label": "von Willebrand -tekijä",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/18/1298/002",
  "fimea_rel_id": "REL51193",
  "authorised_at": "2018-08-31"
}

See everything about von willebrand factor.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.